ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
April 14, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – Tuesday 14, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
ObsEva SA Announces New Interim Chief Financial Officer
April 06, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva SA: New Date Announcement for AGM
March 27, 2020 02:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva Provides Update Related to COVID-19 Pandemic
March 23, 2020 02:00 ET
|
ObsEva SA
Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned PROLONG trial results expected to be announced in 2H:20, as...
ObsEva SA Link to Annual Report 2019
March 05, 2020 04:43 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva Announces Year End 2019 Financial Results and Business Update
March 05, 2020 01:00 ET
|
ObsEva SA
Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month...
ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020
February 27, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – February 27, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
Correction: ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
February 18, 2020 03:48 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
February 18, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
January 15, 2020 01:00 ET
|
ObsEva SA
Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3...